Durable Melanoma Therapy Outcomes in Long-Term ...

By HEOR Staff Writer

June 2, 2026

Five-year data reveal encouraging melanoma therapy outcomes for patients with high-risk stage III/IV melanoma after complete resection. The combination of intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, with K...